Date: Fri 27/09/2019 - Mon 27/09/2021
Optometrist Credits: 1 Clinical Diagnostic Credit
Dispensing Optician Credits: 2 Credits
Event Type(s): Online
Number: +61 2 8336 8616
Clinical trials of VEGF inhibitors for nAMD have reported improved vision for the first time. Data on short and long-term outcomes in routine clinical practice have been studied by the Fight Retinal Blindness! treatment outcomes registry.
The prevalence of vision impairment and blindness in Australia due to neovascular age-related macular degeneration (nAMD) is on the rise due to the growth in the ageing population.1 Individuals with the disease experience difficulties in their routine activities, such as reading, driving and recognising faces, which frequently result in severe impairment in quality of life and loss of independence. This leads to a substantial increase in demands on the Australian health system and in health care costs.